|Articles|April 16, 2007
Fixed-combination products offer option for greater IOP-lowering
Fixed-combination therapies may have a role in glaucoma management when monotherapy reduces IOP but not sufficiently to reach the target level, said Luca Rossetti, MD, professor of ophthalmology, University of Milan, Italy.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
FDA approves carbachol–brimonidine eye drop for presbyopia following phase 3 BRIO trials
2
Sandoz Canada launches aflibercept biosimilar, Enzeevum
3
Noninvasive LED light therapy shows long-term safety in early cataract clinical follow-up
4
AMD and low vision awareness month: Using the MTII to evaluate progression of GA
5
























